Literature DB >> 1556182

Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma).

J D Reveille1, D Owerbach, R Goldstein, R Moreda, R A Isern, F C Arnett.   

Abstract

HLA class II alleles (detected by DNA typing) were determined in 116 Caucasians with systemic sclerosis positive and negative for anticentromere autoantibodies (ACA). Significantly increased frequencies of HLA-DR5(DRw11) (P = 0.009) and the Dw13(DRB1*0403, *0407) subtypes of DR4 (probability corrected, Pc = 0.005) were seen in ACA positive patients, and HLA-DR1 and DRw8 were also increased. These findings appeared to reflect linkage disequilibrium of DR5(DRw11) and many DR4(Dw13) haplotypes with HLA-DQw7 and DR1 with DQw5. In fact, the presence of a DQB1 allele having a polar glycine or tyrosine at position 26 of the DQB1 first domain versus a hydrophobic leucine accounted for 100% of ACA positive Caucasian systemic sclerosis patients compared to 69% of the ACA negative SS patients (P = 0.0008) and 71% of Caucasian controls (P = 0.0003) as well as all 7 ACA patients of non-Caucasian background. Furthermore, the genotype frequency of DQB1 alleles lacking leucine at position 26 was 73% in ACA positive SS patients, compared to 42% of ACA negative patients (P = 1.2 x 10(-5)) and 38% of controls (P = 5.8 x 10(-7)). These data, then, suggest that the second hypervariable region of the HLA-DQB1 chain may form the candidate epitope associated with the ACA response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556182      PMCID: PMC442980          DOI: 10.1172/JCI115704

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-A)/La (SS-B) autoantibody responses.

Authors:  J D Reveille; M J Macleod; K Whittington; F C Arnett
Journal:  J Immunol       Date:  1991-06-01       Impact factor: 5.422

2.  The association of HLA-B8 with visceral disease in systemic sclerosis.

Authors:  P Hughes; K Gelsthorpe; R W Doughty; N R Rowell; F D Rosenthal; I B Sneddon
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

3.  Restriction fragment length polymorphism analysis of HLA-DR, DQ, DP and C4 alleles in Caucasians with systemic lupus erythematosus.

Authors:  J D Reveille; K L Anderson; R E Schrohenloher; R T Acton; B O Barger
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

4.  Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.

Authors:  L J Catoggio; R P Skinner; P J Maddison
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

5.  Increased frequency of HLA-DR5 in scleroderma.

Authors:  D D Gladman; E C Keystone; M Baron; P Lee; D Cane; H Mervert
Journal:  Arthritis Rheum       Date:  1981-06

6.  HLA antigens and scleroderma.

Authors:  M G Ercilla; F Arriaga; M R Gratacós; J Coll; V Lecha; J Vives; R Castillo
Journal:  Arch Dermatol Res       Date:  1981       Impact factor: 3.017

7.  Letter: HL-A antigens in progressive systemic sclerosis (scleroderma).

Authors:  B S Rabin; G P Rodnan; S Bassion; T J Gill
Journal:  Arthritis Rheum       Date:  1975 Jul-Aug

8.  Histocompatibility antigens in progressive systemic sclerosis (scleroderma).

Authors:  N S Birnbaum; G P Rodnan; B S Rabin; S Bassion
Journal:  J Rheumatol       Date:  1977       Impact factor: 4.666

9.  HLA antigens, autoantibodies and clinical subsets in scleroderma.

Authors:  C M Black; K I Welsh; P J Maddison; M I Jayson; R M Bernstein
Journal:  Br J Rheumatol       Date:  1984-11

10.  Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.

Authors:  C G Kallenberg; G W Pastoor; A A Wouda; T H The
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103

View more
  20 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

Review 3.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

4.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

5.  Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes.

Authors:  A Pugliese; T Bugawan; R Moromisato; Z L Awdeh; C A Alper; R A Jackson; H A Erlich; G S Eisenbarth
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

6.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.

Authors:  Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille
Journal:  Ann Rheum Dis       Date:  2009-07-12       Impact factor: 19.103

7.  Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis.

Authors:  David R Karp; Nishanth Marthandan; Steven G E Marsh; Chul Ahn; Frank C Arnett; David S Deluca; Alexander D Diehl; Raymond Dunivin; Karen Eilbeck; Michael Feolo; Paula A Guidry; Wolfgang Helmberg; Suzanna Lewis; Maureen D Mayes; Chris Mungall; Darren A Natale; Bjoern Peters; Effie Petersdorf; John D Reveille; Barry Smith; Glenys Thomson; Matthew J Waller; Richard H Scheuermann
Journal:  Hum Mol Genet       Date:  2009-11-18       Impact factor: 6.150

8.  The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

Authors:  M Kuwana; J Kaburaki; Y Okano; H Inoko; K Tsuji
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

9.  An immunogenetic study of familial scleroderma.

Authors:  M D de Juan; J Belzunegui; I Belmonte; J Barado; M Figueroa; J Cancio; S Vidal; E Cuadrado
Journal:  Ann Rheum Dis       Date:  1994-09       Impact factor: 19.103

10.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.